World's Best Scientists 2026 revealed!
Einar M. Sigurdsson

Einar M. Sigurdsson

D-Index & Metrics

Neuroscience

D-Index
51
Citations
11125
World Ranking
5481
National Ranking
2438

Best Publications

  • Beta-sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy.

    C Soto;E M Sigurdsson;L Morelli;R A Kumar

  • Tau-targeting therapies for Alzheimer disease.

    Erin E. Congdon;Einar M. Sigurdsson

  • Immunotherapy Targeting Pathological Tau Conformers in a Tangle Mouse Model Reduces Brain Pathology with Associated Functional Improvements

    Ayodeji A. Asuni;Allal Boutajangout;David Quartermain;Einar M. Sigurdsson

  • Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging

    J. F. Poduslo;T. M. Wengenack;G. L. Curran;T. Wisniewski

  • Passive immunization targeting pathological phospho-tau protein in a mouse model reduces functional decline and clears tau aggregates from the brain.

    Allal Boutajangout;Johanna Ingadottir;Peter Davies;Einar M. Sigurdsson

  • Immunization with a Nontoxic/Nonfibrillar Amyloid-β Homologous Peptide Reduces Alzheimer's Disease-Associated Pathology in Transgenic Mice

    Einar M. Sigurdsson;Henrieta Scholtzova;Pankaj D. Mehta;Blas Frangione

  • Detection of Alzheimer's amyloid in transgenic mice using magnetic resonance microimaging

    Youssef Zaim Wadghiri;Einar M. Sigurdsson;Marcin Sadowski;James I. Elliott

  • Immunotherapy targeting pathological tau prevents cognitive decline in a new tangle mouse model.

    Allal Boutajangout;David Quartermain;Einar M. Sigurdsson

  • Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory.

    M. Fá;D. Puzzo;D. Puzzo;R. Piacentini;Agnieszka Staniszewski

  • Tau immunotherapy for Alzheimer's disease.

    Jan Torleif Pedersen;Einar M. Sigurdsson

  • Molecular targeting of Alzheimer's amyloid plaques for contrast-enhanced magnetic resonance imaging.

    Joseph F. Poduslo;Thomas M. Wengenack;Geoffry L. Curran;Thomas Wisniewski

  • Postsynaptic degeneration as revealed by PSD-95 reduction occurs after advanced Aβ and tau pathology in transgenic mouse models of Alzheimer’s disease

    Charles Y. Shao;Suzanne S. Mirra;Hameetha B. R. Sait;Todd C. Sacktor

  • Copper chelation delays the onset of prion disease.

    Einar M. Sigurdsson;David R. Brown;Muhammad A. Alim;Henrieta Scholtzova

  • Antibody Uptake into Neurons Occurs Primarily via Clathrin-dependent Fcγ Receptor Endocytosis and Is a Prerequisite for Acute Tau Protein Clearance

    Erin E. Congdon;Jiaping Gu;Hameetha B.R. Sait;Einar M. Sigurdsson

  • Two Novel Tau Antibodies Targeting the 396/404 Region Are Primarily Taken Up by Neurons and Reduce Tau Protein Pathology

    Jiaping Gu;Erin E. Congdon;Einar M. Sigurdsson

  • An Attenuated Immune Response Is Sufficient to Enhance Cognition in an Alzheimer's Disease Mouse Model Immunized with Amyloid- Derivatives

    Einar M. Sigurdsson;Elin Knudsen;Ayodeji Asuni;Cheryl Fitzer-Attas

  • A synthetic peptide blocking the apolipoprotein E/β-amyloid binding mitigates β-amyloid toxicity and fibril formation in vitro and reduces β-amyloid plaques in transgenic mice

    Marcin Sadowski;Joanna Pankiewicz;Henrieta Scholtzova;James A. Ripellino

  • Immunotherapy targeting pathological tau protein in Alzheimer's disease and related tauopathies.

    Einar M. Sigurdsson

  • Memantine leads to behavioral improvement and amyloid reduction in Alzheimer's-disease-model transgenic mice shown as by micromagnetic resonance imaging.

    Henrieta Scholtzova;Youssef Z. Wadghiri;Moustafa Douadi;Einar M. Sigurdsson

  • In vivo reversal of amyloid-β lesions in rat brain

    Einar M. Sigurdsson;Bruno Permanne;Claudio Soto;Thomas Wisniewski

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: